Prof. Dr Wolfgang Plischke Consultant, Chairman of the Supervisory Board of Evotec Prof. Dr Wolfgang Plischke (born in 1951, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 for a term of five years and has since then served as Chairman of the Supervisory Board. His current term will expire at the end of the AGM held in the year 2019. From March 2006 until April 2014, Prof. Dr Wolfgang Plischke has been a member of the Board of Management of Bayer AG. He was responsible for Technology, Innovation and Sustainability and for the Asia/Pacific region. From January 2002 to February 2006, he was Head of the Pharmaceuticals Business Group at Bayer AG with responsibility for the global business with prescription drugs. From 2000 to 2002, he served as Head of the Pharmaceuticals Business Group in North America at Bayer AG. From 1995 to 2000, Prof. Dr. Plischke served as President of Bayer Yakuhin Ltd., Japan, with responsibility for Pharmaceuticals and Consumer Care. He began his career in 1980 with Bayer’s subsidiary Miles Diagnostics after completing his biology studies at Hohenheim University. Prof. Dr Plischke has been member of the Supervisory Board of Bayer AG since April 2016. He also holds a number of offices outside of Bayer AG. He is a member of the Board of the Walter Siegenthaler Society and the Robert Koch Foundation. Prof. Plischke is also a member of the senate of the Helmholtz association. In July 2011, Prof. Dr Wolfgang Plischke was appointed honorary professor for Business Chemistry at the Ludwig Maximilian University of Munich.

Bernd Hirsch CFO of Bertelsmann SE & Co. KGaA, Vice Chairman of the Supervisory Board of Evotec Bernd Hirsch (born in 1970, German citizen) was elected Vice Chairman of the Supervisory Board on 09 June 2015. He was appointed Member of the Supervisory Board in June 2014 for a term of five years. His current term will expire at the end of the AGM held in the year 2019.On 16 December 2013, Bernd Hirsch was appointed Member of the Supervisory Board by the commercial register court Hamburg at the application of the Company. Born in Ellwangen, Germany, Bernd Hirsch completed his degree in business administration at the University of Würzburg and afterwards gained significant experience in various leading positions in the financial area. From 1998 to 2001, he was Audit Manager at the audit firm Arthur Andersen. In 2001, he started at Carl Zeiss Group as Head of Mergers & Acquisitions. One year later, Bernd Hirsch was appointed Chief Financial Officer and member of the Executive Board at Carl Zeiss Meditec AG. From December 2009 to December 2015, Bernd Hirsch was Chief Financial Officer and member of the Executive Board of Symrise AG. From 01 April 2016 onwards, Bernd Hirsch has been Chief Financial Officer of Bertelsmann SE & Co. KGaA. Furthermore, he acts as Director of Bertelsmann Inc., Penguin Random House LLC, and RTL Group S.A. Apart from his role as member of the Supervisory Board of Evotec AG, he does not hold memberships in any other comparable supervisory bodies.

Dr Claus Braestrup Consultant Dr Claus Braestrup (born in 1945, Danish citizen) was appointed Member of the Supervisory Board on 12 June 2013 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2014 in June 2014 for a term of five years. His current term will expire at the end of the AGM held in the year 2019. During his career, he gained extensive experience from publicly traded international pharmaceutical companies as well as scientific and drug discovery qualifications. From 2003 to 2008, Dr Braestrup served as president and CEO at H. Lundbeck A/S, where he was head of research and development from 1998 to 2003. Previously, he served as head of pre-clinical drug research at Schering AG from 1994 to 1998, at Novo Nordisk A/S as president of the Diabetes Care Division (1993-1994), president of its CNS Division (1988-1993) and vice president of pharmaceutical research (1984-1988) and at Ferrosan A/S as scientist in drug discovery from 1978 to 1984. He serves as Non-Executive Chairman of the Board of Directors of Saniona AB and as Non-Executive Member of the Board of Directors of Bavarian Nordic A/S and Kastan ApS. Dr Braestrup holds a Master’s degree in Chemical Engineering and is Master of Science in Biochemistry. He is Doctor of Medical Science and former Adjunct Professor in Neuroscience at the University of Copenhagen.

Prof. Dr Iris Löw-Friedrich Chief Medical Officer and Head of Development & Medical Practices of UCB S.A. Prof. Dr Iris Löw-Friedrich (born in 1960, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 for a term of five years. Her current term will expire at the end of the AGM held in the year 2019. Since March 2008, Prof. Dr Iris Löw-Friedrich has been serving as Chief Medical Officer and Head of Development & Medical Practices of UCB S.A., Brussels, Belgium. From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen. From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA. Since April 2014, she has been Member of the Supervisory Board at TransCelerate BioPharma Inc (Chairman of the Supervisory Board from September 2015 until September 2017). Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA. Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000. She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985.

Michael Shalmi Managing Director, Head of Principal Investments, Novo Holdings A/S Mr Michael Shalmi (born in 1965, Danish citizen) was appointed Member of the Supervisory Board on 14 June 2017 for a term of two years. His current term will expire at the end of the AGM held in the year 2019. Since January 2017, Mr Michael Shalmi has been Managing Director, Head of Principal Investments of Novo Holdings A/S. From 2009 to 2016, he served as Senior Partner at Novo Holdings A/S where he led at first the division Novo Growth Equity and then for two years the division Large Investments. In this role, he was responsible for the strategic long-term investments in life science. Prior to his career at Novo Holdings A/S, he spent 15 years at Novo Nordisk A/S where he held a number of different international management positions in research, clinical development as well as marketing and management, lastly as Vice President, Global Development, Clinical Operations Management. Prior to working at Novo Nordisk, he was research associate at the universities in Copenhagen and Manchester. During his career, Michael Shalmi gained extensive expertise in medicine and especially focused on drug and product development and on the development of commercialisation strategies. Mr Shalmi holds further positions as a member of other statutory supervisory boards such as Member of the Supervisory Board of Orexo AB, Synlab Ltd., Momentum Gruppen A/S, ERT Inc., ERT HoldCo A/S, Xellia HoldCo A/S and Novo Invest 1 A/S. Mr Shalmi received his Doctorate of Medicine from the University in Copenhagen and his MBA degree from the Scandinavian International Management Institute.

Dr Elaine Sullivan Chief Executive Officer of Carrick Therapeutics Ltd Dr Elaine Sullivan (born in 1961, British citizen) was appointed Member of the Supervisory Board on 09 June 2015 for a term of four years. Her current term will expire at the end of the AGM held in the year 2019. Since January 2015, Dr Sullivan has been Chief Executive Officer of Carrick Therapeutics Ltd, a new European oncology company. Elaine Dr Sullivan has worked as part of top management teams in R&D at Eli Lilly and AstraZeneca. She has over 25 years of international experience working in the Pharmaceutical industry in the US, Switzerland and the UK. From 2011 to 2014, she served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, IN, USA, where she led a global workforce delivering access to business critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly’s Capital Fund partners. Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca from 1995 until 2010, including Vice-President R&D, New Opportunities, from 2007 to 2010. In this role, she established and led AstraZeneca‘s virtual Therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer, ophthalmology and respiratory and inflammation. Furthermore, she has particular expertise in origination, development and execution of innovative partnerships. Since July 2015, Dr Elaine Sullivan has been serving as Member of the Supervisory Board of the IP Group plc. Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor’s degree in Molecular Biology from the University of Glasgow, UK.

TOP